2888-63-3

Usage

Uses

Used in Pharmaceutical Research:
(E)-2-chloro-N-[4-chloro-2-[(hydroxyimino)phenylmethyl]phenyl]acetamide is used as a research compound for exploring its interactions with biological systems. Its molecular structure and functional groups provide insights into its potential as a drug candidate, offering a foundation for further development and optimization in medicinal chemistry.
Used in Drug Development:
In the pharmaceutical industry, (E)-2-chloro-N-[4-chloro-2-[(hydroxyimino)phenylmethyl]phenyl]acetamide is utilized as a starting point for the design and synthesis of new drugs. Its unique properties and potential biological activity make it a promising candidate for the treatment of various diseases and conditions, subject to further investigation and validation.
Used in Laboratory Settings:
(E)-2-chloro-N-[4-chloro-2-[(hydroxyimino)phenylmethyl]phenyl]acetamide is employed in laboratory experiments to study its chemical and physical properties, as well as its reactivity with other compounds. This information is crucial for understanding its behavior in biological systems and for guiding its application in drug development.

InChI:InChI=1/C15H12Cl2N2O2/c16-9-14(20)18-13-7-6-11(17)8-12(13)15(19-21)10-4-2-1-3-5-10/h1-8,21H,9H2,(H,18,20)

Upstream product

• 15185-66-7 (2-amino-5-chlorophenyl)(phenyl)methanone oxime 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 604-75-1 oxazepam 

Relevant academic research and scientific papers

In vivo evaluation of substituted 3-amino-1,4-benzodiazepines as anti-depressant, anxiolytic and anti-nociceptive agents

Oxazepam (CAS 604-75-1) 4 a served as building block in the synthesis of substituted 3-amino-l,4-benzodiazepines, which were subsequently tested in various CNS animal models. The hydroxy group of oxazepam was either activated as a chloride (Method A) or as a phos- phor-oxy derivative (Method B) giving the desired 3-amino-l,4-benzodiapines 6 a- 6r in high yields with primary and secondary amines in a typical nucleophilic substitution reaction. Eighteen 3-substi- tuted 1,4-benzodiazepines were prepared and served as new chemical entities and for lead structure discovery. The mixed cholecystokinin (CCK) antagonist 6 e showed anxiolytic and antidepressant effects from 10μg/kg in mice in the elevated x-maze test and the forced swimming test. The CCK 1 antagonist 6 g has shown antidepressant effects from the same dose, but lacked anxiolytic properties. Both compounds potentiated at a dose of 0.5 mg/kg morphine antinocicep- tion with a maximum possible effect (MPE) about 35 %. By assessing initially the MPE of antinocipection for the 18 newly synthesised benzodiazepines in the tail-flick test, 4 other benzodiazepines were found active. In further in vivo evaluation the cyclohexyl derivative 6 i displayed anxiolytic, antidepressant and antinociceptive properties as single agent at a dose of 5 mg/kg without toxicity. The benzodiazepines 6i and 6p, which initially showed a higher MPE in terms of morphine potentiation (43/44%) showed analgesic effects as single agents, without having anxiolytic or antidepressant properties. The amino-piperidinyl derivative 6 p displayed a similar dose-response relationship to morphine, but was 3 times more potent. ECV Editio Cantor Verlag, Aulendorf (Germany).